Strong increase in revenues and theranostics sales and signature of two partnership agreements with pharmaceutical companiesProduct sales rise to 3.4 M€Doubling of theranostic sales Signature of collaborative agreements with two pharmaceutical companiesCroissy-Beaubourg and Montpellier, September…
Theradiag reaches new milestone in the development of two new theranostics tests in rectal cancerTheradiag secures access to multicentric patient cohorts with two leading cancer research partnersCroissy-Beaubourg and Montpellier, July 22, 2015 – Theradiag (ISIN:…
Further validation of routine biotherapy monitoring in IBD patientsUndetectable anti-TNF drug levels in IBD patients with long-term remission predicts relapse-free survival after drug withdrawal Croissy-Beaubourg and Montpellier, June 17, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER),…